Trial Profile
A multi-center randomized phase II study to evaluate the combination therapy of substitution of antiandrogens and tegafur-uracil for castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2015
Price :
$35
*
At a glance
- Drugs Tegafur/uracil (Primary) ; Antiandrogens
- Indications Prostate cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 24 Oct 2012 Status changed from active, no longer recruiting to completed.
- 07 Jun 2011 Updated results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 15 Jun 2010 New trial record